First magic mushroom depression trial hits stumbling block

By REUTERS
April 7, 2013 02:02

LONDON- The world's first clinical trial designed to explore using a hallucinogen from magic mushrooms to treat people with depression has stalled because of British and European rules on the use of illegal drugs in research.

David Nutt, president of the British Neuroscience Association and professor of neuropsychopharmacology at Imperial College London, said he had been granted an ethical green light and funding for the trial, but regulations were blocking it."We live in a world of insanity in terms of regulating drugs," he told a neuroscience conference in London on Sunday.

He has previously conducted small experiments on healthy volunteers and found that psilocybin, the psychedelic ingredient in magic mushrooms, has the potential to alleviate severe forms of depression in people who don't respond to other treatments.


Related Content

Breaking news
October 15, 2019
Ecuador's Moreno signs decree ditching fuel subsidy cuts after protests

By REUTERS

Cookie Settings